Lupin achieves S&P Global ESG score of 91
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Enabling a new era in minimally invasive obesity treatment across Europe
Subscribe To Our Newsletter & Stay Updated